Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors
Treatment with ASP9801 alone or plus pembrolizumab was generally well tolerated; however, the study was stopped due to lack of efficacy during dose expansion.
Authors
- Leshi Zhang (ORCID: https://orcid.org/0009-0005-9664-8593)
- Manish R. Patel (ORCID: https://orcid.org/0000-0001-6836-2364)
- Serguei Soukharev
- Kristopher Wentzel
- Shunsuke Yamada (ORCID: https://orcid.org/0000-0001-5511-7511)
- Michael Chisamore (ORCID: https://orcid.org/0009-0006-8629-8232)
- Ricklie Julian
- J. L. Villano
- Shigeru Takeshita
- Jason Luke
- Christos Fountzilas
- Pranob Bhattacharya
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Roswell Park Comprehensive Cancer Center (US)
- University of Minnesota (US)
- University of Arizona (US)
- Astellas Pharma (Japan) (JP)
- University of Kentucky (US)
- Astellas Pharma (China) (CN)
- Angeles Clinic and Research Institute (US)
- UPMC Hillman Cancer Center (US)
- University of Pittsburgh Medical Center (US)
- Arizona Oncology (US)
- Astellas Pharma (United States) (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/jitc-2025-012377
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Society for Immunotherapy of Cancer
- National Comprehensive Cancer Network
- Tizona Therapeutics
- Incyte
- Moderna
- MacroGenics
- Astellas Pharma
- Servier
- Ipsen
- National Institutes of Health
- EMD Serono
- National Cancer Institute